Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

被引:172
作者
Hansen, C. R. [1 ]
Pressler, T. [1 ]
Hoiby, N. [2 ]
机构
[1] Rigshosp, Dept Pediat, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen Hosp, Rigshosp, Dept Clin Microbiol, DK-2100 Copenhagen, Denmark
关键词
Cystic fibrosis; Pseudomonas aeruginosa; Colomycin; Ciprofloxacin; Pulmonary infection;
D O I
10.1016/j.jcf.2008.06.009
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Since 1989, CF-patients intermittently colonized with Pseudomonas aeruginosa have been treated with inhaled colistin and oral ciprofloxacin in the Copenhagen CF-centre. The study evaluates 15 years results of this treatment. Methods: All isolates of P aeruginosa from CF-patients intermittently colonized with P. aeruginosa from 1989 to 2003 were identified All antiP. aeruginosa treatments were evaluated for antibiotics used, treatment duration, pseudomonas-free interval and development of chronic infection. All P. aeruginosa isolates were assessed for resistance and for non-mucoid or mucoid phenotype. Results: 146 CF-patients were included in the study (1106 patient-years). 99 patients had first ever isolate during the study period. Median observation time 7 years (0.1-14.9). 12 patients developed chronic infection. A Kaplan Meyer plot showed protection from chronic infection in up to 80% of patients for up to 15 years. 613 colistin/ciprofloxacin treatments were given. There was no difference in pseudo in on as-free interval comparing 3 weeks (5 months) and 3 months (10.4 months) of colistin and ciprofloxacin, but a significant difference compared to no treatment (1.9 months). Patients developing chronic infection had significantly shorter pseudo monas-free interval after treatment of first ever isolate compared to patients remaining intermittently colonized (p<0.003). Treatment failure (P aeruginosa-positive Culture immediately after ended treatment of first ever isolate) was a strong risk factor for development of chronic infection after 3-4 years, OR 5.8. 1093 pseudomonas-isolates were evaluated (86.6% non-mucoid). No colistin-resistance was found. Ciprofloxacin-resistance was found in 4% of isolates. Conclusion: Treatment of intermittent P. aeruginosa colonization in CF-patients using colistin and ciprofloxacin can protect tip to 80% of patients from development of chronic infection for tip to 15 years. A positive culture immediately after treatment of first ever isolate is a strong risk factor for development of chronic infection. We found no colistin-resistance and minimal ciprofloxacin-resistance. (C) 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:523 / 530
页数:8
相关论文
共 51 条
[1]   BSAC standardized disc susceptibility testing method (version 6) [J].
Andrews, J. M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (01) :20-41
[2]   Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis [J].
Burns, JL ;
Gibson, RL ;
McNamara, S ;
Yim, D ;
Emerson, J ;
Rosenfeld, M ;
Hiatt, P ;
McCcoy, K ;
Castile, R ;
Smith, AL ;
Ramsey, BW .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (03) :444-452
[3]   Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients [J].
Cantón, R ;
Cobos, N ;
de Gracia, J ;
Baquero, F ;
Honorato, J ;
Gartner, S ;
Alvarez, A ;
Salcedo, A ;
Oliver, A ;
García-Quetglas, E .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (09) :690-703
[4]   Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation [J].
Ciofu, O ;
Riis, B ;
Pressler, T ;
Poulsen, HE ;
Hoiby, N .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2276-2282
[5]   DEVELOPMENT OF ANTIBIOTIC-RESISTANCE IN PSEUDOMONAS-AERUGINOSA DURING 2 DECADES OF ANTIPSEUDOMONAL TREATMENT AT THE DANISH-CF-CENTER [J].
CIOFU, O ;
GIWERCMAN, B ;
PEDERSEN, SS ;
HOIBY, N .
APMIS, 1994, 102 (09) :674-680
[6]   Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center [J].
Denton, M ;
Kerr, K ;
Mooney, L ;
Keer, V ;
Rajgopal, A ;
Brownlee, K ;
Arundel, P ;
Conway, S .
PEDIATRIC PULMONOLOGY, 2002, 34 (04) :257-261
[7]   Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis:: a European consensus [J].
Döring, G ;
Conway, SP ;
Heijerman, HGM ;
Hodson, ME ;
Hoiby, N ;
Smyth, A ;
Touw, DJ .
EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (04) :749-767
[8]  
Frederiksen B, 1999, PEDIATR PULM, V28, P159, DOI 10.1002/(SICI)1099-0496(199909)28:3<159::AID-PPUL1>3.0.CO
[9]  
2-1
[10]  
Frederiksen B, 1997, PEDIATR PULM, V23, P330, DOI 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO